🎉 M&A multiples are live!
Check it out!

Proteomics International Valuation Multiples

Discover revenue and EBITDA valuation multiples for Proteomics International and similar public comparables like Avacta Group, Genomictree, and Biohit.

Proteomics International Overview

About Proteomics International

Proteomics International Laboratories Ltd is a biological research and drug discovery company. The company specializes in the area of proteomics which is the industrial-scale study of the structure and function of proteins. Its operations are divided into PromarkerD which targets the diabetes epidemic and is a predictive diagnostic test for diabetic kidney disease, a progressive disorder found in one in three adults with diabetes; its proprietary biomarker discovery platform called Promarker, which searches for protein fingerprints in a sample; and Analytical Services that are specialist contract research focusing on biosimilars quality control and pharmacokinetic testing for clinical trials.


Founded

2014

HQ

Australia
Employees

n/a

Financials

LTM Revenue $2.4M

LTM EBITDA -$3.9M

EV

$35.5M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Proteomics International Financials

Proteomics International has a last 12-month revenue of $2.4M and a last 12-month EBITDA of -$3.9M.

In the most recent fiscal year, Proteomics International achieved revenue of $0.6M and an EBITDA of -$5.3M.

Proteomics International expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Proteomics International valuation multiples based on analyst estimates

Proteomics International P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $0.5M $0.6M XXX XXX XXX
Gross Profit $0.9M $0.5M XXX XXX XXX
Gross Margin 204% 82% XXX XXX XXX
EBITDA -$5.2M -$5.3M XXX XXX XXX
EBITDA Margin -1135% -941% XXX XXX XXX
Net Profit -$3.1M -$3.9M XXX XXX XXX
Net Margin -681% -699% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Proteomics International Stock Performance

As of April 15, 2025, Proteomics International's stock price is AUD 0 (or $0).

Proteomics International has current market cap of AUD 61.6M (or $38.7M), and EV of AUD 56.5M (or $35.5M).

See Proteomics International trading valuation data

Proteomics International Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$35.5M $38.7M XXX XXX XXX XXX $-0.03

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Proteomics International Valuation Multiples

As of April 15, 2025, Proteomics International has market cap of $38.7M and EV of $35.5M.

Proteomics International's trades at 15.1x LTM EV/Revenue multiple, and -9.1x LTM EBITDA.

Analysts estimate Proteomics International's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Proteomics International and 10K+ public comps

Proteomics International Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $35.5M XXX XXX XXX
EV/Revenue 24.1x XXX XXX XXX
EV/EBITDA -7.7x XXX XXX XXX
P/E -9.3x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -8.8x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Proteomics International Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Proteomics International Valuation Multiples

Proteomics International's NTM/LTM revenue growth is 22%

Proteomics International's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.

Over next 12 months, Proteomics International's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Proteomics International's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Proteomics International and other 10K+ public comps

Proteomics International Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 22% XXX XXX XXX XXX
EBITDA Margin -311% XXX XXX XXX XXX
EBITDA Growth 1% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -289% XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee n/a XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 622% XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue 1123% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Proteomics International Public Comps

See public comps and valuation multiples for Pharma Diagnostics & Analytics and Health Data & Analytics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Zomedica XXX XXX XXX XXX XXX XXX
AnteoTech XXX XXX XXX XXX XXX XXX
Biohit XXX XXX XXX XXX XXX XXX
Genomictree XXX XXX XXX XXX XXX XXX
Avacta Group XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Proteomics International M&A and Investment Activity

Proteomics International acquired  XXX companies to date.

Last acquisition by Proteomics International was  XXXXXXXX, XXXXX XXXXX XXXXXX . Proteomics International acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Proteomics International

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Proteomics International

When was Proteomics International founded? Proteomics International was founded in 2014.
Where is Proteomics International headquartered? Proteomics International is headquartered in Australia.
Is Proteomics International publicy listed? Yes, Proteomics International is a public company listed on ASX.
What is the stock symbol of Proteomics International? Proteomics International trades under PIQ ticker.
When did Proteomics International go public? Proteomics International went public in 2015.
Who are competitors of Proteomics International? Similar companies to Proteomics International include e.g. Zomedica, AnteoTech, Biohit, Genomictree.
What is the current market cap of Proteomics International? Proteomics International's current market cap is $38.7M
What is the current revenue of Proteomics International? Proteomics International's last 12-month revenue is $2.4M.
What is the current EBITDA of Proteomics International? Proteomics International's last 12-month EBITDA is -$3.9M.
What is the current EV/Revenue multiple of Proteomics International? Current revenue multiple of Proteomics International is 15.1x.
What is the current EV/EBITDA multiple of Proteomics International? Current EBITDA multiple of Proteomics International is -9.1x.
What is the current revenue growth of Proteomics International? Proteomics International revenue growth between 2023 and 2024 was 22%.
Is Proteomics International profitable? Yes, Proteomics International is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.